The Swiss firm expects no generic versions of Gilenya in the US market "for at least the next two years" after a court again ruled against HEC Pharma, the only remaining company challenging its patent.

AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.

India's Sun Pharmaceutical Industries has said it is seeking "well-managed" acquisition targets -- unlike its 2015 purchase of troubled rival Ranbaxy which continues to absorb “significant” management time – at the same time as pressing ahead with its consolidation drive with the disposal of two US plants.

India's Sun Pharma has clinched a deal to sell a US plant as part of a consolidation drive in the wake of its purchase of rival Ranbaxy, amid improving investor sentiment toward the country's biggest drug company.